Skip to content

Shop
Scholar
Lab Results
Learn
Vote
Forum
About

Search Kodiac

Sign in Sign up Account

Tag: MONOGRAPH

Thyrotropin-Releasing Hormone (TRH)

Hypothalamic tripeptide (thyrotropin-releasing hormone)

A hypothalamic tripeptide that triggers pituitary TSH release; used as a pharmacological probe for pituitary function and investigated for cognitive enhancement.

Abstract

TRH (thyrotropin-releasing hormone; pyroglutamyl-histidyl-prolinamide; CAS 24305-27-9; molecular formula C16H22N6O4; molecular weight 362.39) is a hypothalamic tripeptide that activates pituitary TRH receptors to trigger TSH release. Discovered independently by Schally and Guillemin in the late 1960s (Nobel Prize 1977). The compound is the smallest peptide hormone of the hypothalamic-pituitary axis. Pharmacologically, exogenous TRH has been used as a clinical probe of pituitary thyrotroph function (the TRH stimulation test, now largely supplanted by sensitive TSH assays). Beyond TSH release, TRH receptors are distributed throughout the CNS and TRH has direct effects on arousal, mood, and cognitive function; clinical trials in depression, ALS, and spinocerebellar ataxia have been mixed. Plasma half-life is approximately 5 minutes, severely limiting clinical use; analog development has produced taltirelin (approved in Japan for spinocerebellar degeneration) and other TRH receptor agonists with extended pharmacokinetics. Used as the canonical hypothalamic peptide for pituitary axis research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-290Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Vincamine

Plain-language summaryIntrigue 35 / 100

Vincamine is the natural indole alkaloid extracted from Vinca minor (lesser periwinkle), the parent compound that vinpocetine was derived from. It shares the cerebral-vasodilation and modest phosphodiesterase-inhibition profile with vinpocetine but is shorter-acting and less lipophilic. Approved in France (as Pervincamine) and Italy for cerebrovascular insufficiency and mild dementia. Largely supplanted by vinpocetine in markets where both are available, owing to the latter’s better pharmacokinetics. Of mainly historical interest as the natural starting point for the eburnane vasodilator class. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

28/100

Parent compound of vinpocetine; superseded by its own derivative with limited independent research value

Look, vincamine occupies a specific and somewhat awkward position in the research landscape: it’s the parent compound of vinpocetine, which means its most important historical contribution was getting chemically modified into something better. That’s not a great story for a research target in 2026.

The mechanism isn’t the issue per se. Cerebral vasodilation via smooth muscle relaxation, mild PDE inhibition, some antioxidant activity in mitochondrial fractions. These are real biological effects, but they’re not novel and have been well-characterized for decades. France approved it as Pervincamine; Italy uses it for cerebrovascular insufficiency and age-related cognitive decline. That approval history gives it more clinical anchoring than most peptides on research shelves, which is something. But the underlying mechanism class has had a rough few decades in terms of clinical translation for dementia-adjacent indications, and vincamine specifically isn’t a bright spot in that story.

The differentiation problem is hard to argue around. Vinpocetine is more lipophilic, crosses the blood-brain barrier more efficiently, has a longer half-life (roughly 2-3 hours vs vincamine’s approximately 1 hour), and carries substantially more published literature from independent groups. If you’re asking a bench-level question about the eburnane alkaloid scaffold, vincamine is the historical reference; it’s not the compound you’d choose to answer that question with today. The derivative wins almost every comparison you’d care about.

Thats not to say vincamine is worthless. For labs doing comparative scaffold chemistry, looking at the eburnane core versus its semisynthetic variants, vincamine is the natural starting material and the reference point. There’s legitimate synthetic and pharmacokinetics work where having the parent compound matters. We also think the European approved-drug status means the safety and tolerability file is cleaner than for most research compounds in this space, and the multi-decade literature gives you methodological precedent to work from.

What we don’t like is how little of that literature is modern, replicated by independent groups, or aimed at anything beyond the fairly ill-defined category of cerebrovascular insufficiency, an indication the field has largely moved away from. Most of the published clinical work predates 2000 and is of variable methodological quality by current standards.

Honestly, if you’re building out an eburnane scaffold comparative program, vincamine belongs in the collection as a reference compound. For any other purpose, the resource allocation case is weak. Vinpocetine does what vincamine does, only better, which is a hard position to argue your way out of.

Novelty

22

Mechanism promise

27

In-category differentiation

18

Evidence quality

38

Translational signal

40

Research bench value

32

Rationale Vincamine scores poorly on novelty and differentiation because it’s a decades-old European-approved cerebrovascular agent whose semisynthetic derivative outperforms it on nearly every pharmacokinetic and research-utility dimension; evidence quality is modest given the largely pre-modern clinical literature, and the mechanism is unremarkable cerebrovascular dilation plus weak PDE inhibition.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Periwinkle alkaloid / cerebrovascular agent

An indole alkaloid from Vinca minor; the parent compound of vinpocetine, used as a cerebrovascular agent in Europe.

Abstract

Vincamine ((3-alpha,14-beta,16-alpha)-14,15-dihydro-14-hydroxyeburnamenine-14-carboxylic acid methyl ester; CAS 1617-90-9; molecular formula C21H26N2O3; molecular weight 354.45) is an indole alkaloid isolated from Vinca minor (lesser periwinkle). The compound is the natural precursor of vinpocetine, sharing the eburnane scaffold but with reduced lipophilicity and shorter duration of action. Mechanism: cerebral vasodilation, modest PDE inhibition, antioxidant activity. Approved in several European countries (notably France as Pervincamine and Italy) for cerebrovascular insufficiency, mild dementia, and age-related cognitive decline. Plasma half-life is approximately 1 hour; oral bioavailability is moderate. Used as a cerebrovascular agent in academic research and as the historical reference compound for the eburnane class.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-306Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Cannabinol (CBN)

Our opinion on this compoundOverhyped vs evidence

20/100

Heavily marketed sleep compound built on a 1976 trial, likely a THC-contamination artifact, with nothing new to offer bench researchers

Look, CBN is a compound that exists primarily because THC gets old. Oxidative degradation of delta-9-THC produces the aromatized A-ring structure we call cannabinol, and that single structural shift costs roughly 90 percent of CB1 binding potency. What you’re left with is a weak partial agonist at CB1, roughly comparable CB2 affinity, and a compound that the supplement industry has decided to rebrand as the ‘sleep cannabinoid.’ The branding is confident. The science is not.

The sleep claim is the central problem here. The evidence base is genuinely thin. The foundational clinical reference is a 1976 trial, one trial, almost fifty years old, small N, and critically the samples used almost certainly contained residual THC. When investigators have tried to untangle CBN-specific sedation from THC contamination in subsequent work, the effect largely disappears or collapses to noise. We dont have a single clean, well-powered, replicated clinical demonstration that CBN produces sleep induction attributable to CBN itself. The marketing has outrun the science by a generation, and that gap shows no sign of closing.

From a mechanism standpoint, theres not much to get excited about. Weak CB1 partial agonism is solved and somewhat boring pharmacological territory. The CB2 affinity is real and occasionally cited in inflammatory or pain contexts, but purpose-built CB2 agonists with cleaner selectivity profiles already exist for those questions. Some recent work has floated TRPA1 interactions, but this is early, small, and not replicated anywhere that matters yet. The aromatized ring system is chemically interesting as a structure-activity story, but it doesnt translate into novel pharmacology that investigators couldnt access more precisely with other tools.

Differentiation is the weakest axis. CBN isn’t best-in-class at anything. For CB1 work, THC and a library of synthetic cannabinoids do it better. For CB2 selectivity, purpose-built agonists exist. For sleep pharmacology, you’d reach for something with actual trial data. The only reason CBN ends up on procurement lists is structural adjacency to THC in certain regulatory gray zones, which is a sourcing rationale, not a scientific one.

Honestly, the compound sits in a frustrating middle ground: not scheduled tightly enough to carry the protected-probe cachet that justifies access friction in rigorous cannabinoid programs, but not clean enough to treat as a reliable OTC research tool either. A serious cannabinoid pharmacology lab doesn’t need CBN specifically to answer the questions CBN nominally addresses. The hype is real. The compound isn’t. Score reflects that.

Novelty

22

Mechanism promise

22

In-category differentiation

15

Evidence quality

18

Translational signal

15

Research bench value

28

Rationale CBN scores low across nearly every axis: it’s a decades-old THC degradation product with weak receptor pharmacology, its signature claim of sleep induction likely reflects THC contamination in historical samples, and better CB1/CB2 probes exist for any research question it might address. Uncapped score lands at 20, well below any structural cap that would otherwise apply.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Phytocannabinoid (THC degradation product)

A phytocannabinoid produced by THC oxidation in aged cannabis; weakly intoxicating; widely marketed as a sleep aid despite limited clinical evidence.

Abstract

Cannabinol (CBN; CAS 521-35-7; molecular formula C21H26O2; molecular weight 310.43) is a phytocannabinoid formed primarily by oxidative degradation of THC; aged cannabis develops higher CBN concentrations. The compound retains weak CB1 partial agonist activity (approximately 10 percent of THC potency at CB1), producing mild psychoactive effects at high doses. CB2 affinity is comparable to or higher than CB1. Pharmacologically distinguished from THC by the aromatized A-ring, which reduces CB1 binding but preserves other interactions. Marketing claims position CBN as a sleep aid; clinical evidence for this is limited (one 1976 trial and small subsequent studies), and the sedation may largely reflect residual THC contamination in early CBN samples. Plasma kinetics parallel other cannabinoids. Used as a CB receptor partial agonist research compound; the sleep marketing claims await rigorous clinical validation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-322Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Harmine

Plain-language summaryIntrigue 68 / 100

Harmine is the second major beta-carboline in ayahuasca and Syrian rue, with the same reversible MAO-A inhibition that lets oral DMT work. What makes harmine separately interesting is its activity as a DYRK1A kinase inhibitor at low nanomolar potency. DYRK1A regulates pancreatic beta-cell proliferation, and harmine has emerged as a tool compound for stimulating beta-cell regrowth in diabetes research, where adult beta-cells have been considered essentially non-replicative. That diabetes angle is genuinely novel and has driven medicinal chemistry programs to build cleaner DYRK1A inhibitors without the MAO baggage. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

49/100

Dual MAO-A and DYRK1A inhibitor; the reference probe that opened human beta-cell regeneration research

Harmine has been around long enough that it almost feels unfair to call it a research compound. Beta-carboline alkaloids from Peganum harmala were being studied before most modern pharmacology existed. The MAO-A inhibition story is mature, well-documented, and not particularly interesting by itself: reversible MAOI in a crowded class, solid selectivity over MAO-B, short plasma half-life around 1 to 3 hours. If that were the whole story, we’d score it low and move on.

The DYRK1A angle is what keeps harmine on our radar. The Bhatt lab at Icahn Mount Sinai (now Garcia-Ocana at Cedars-Sinai) dropped a Nature Medicine paper in 2015 showing that harmine, operating as a DYRK1A kinase inhibitor at roughly 30 nM IC50, could drive human pancreatic beta-cell proliferation at a level nobody had seen before with a small molecule. Beta-cell regeneration has been a target for type 1 and type 2 diabetes research for decades; thats genuinely hard biology, and harmine hit it in a way that attracted serious attention. Follow-up work confirmed the effect in humanized mouse models, and the field has since spawned cleaner derivative compounds now entering Phase 1 trials.

The evidence situation is complicated. The beta-cell story is well-replicated within the Bhatt/Garcia-Ocana group and their collaborators, and the preclinical methodology is solid. But the work remains consortium-concentrated. You get multi-lab confirmation in the sense that several groups have used harmine as a probe, but the primary mechanistic claims on beta-cell expansion still trace back to a tight cluster of investigators. That’s not a knock; the data quality is real. It just means we’re not looking at the kind of multi-institutional replication you’d want before calling it settled science.

As a bench tool, harmine earns its place. It’s the reference beta-carboline for ayahuasca pharmacology research, and it’s the compound that opened the DYRK1A/beta-cell proliferation story as a tractable target. More selective DYRK1A inhibitors have emerged since (GNF4877, INDY, the leucettine series), so if youre doing clean kinase biology, those are better probes now. But harmine’s dual MAO-A/DYRK1A activity is genuinely useful when you want to understand what the full beta-carboline scaffold does across both axes simultaneously, or when sourcing a historically-grounded reference standard for the class.

What we don’t love: the MAO-A inhibition is a real confound for any harmine-specific mechanistic experiment, and the CNS activity profile makes whole-animal results harder to interpret cleanly. What we like: it remains the canonical probe for a research area with real translational momentum, and the derivative pipeline it inspired is one of the more interesting small-molecule diabetes programs currently running. Solid established-active scoring, with genuine upside in the DYRK1A space if replication continues to hold outside the founding consortium.

Novelty

42

Mechanism promise

62

In-category differentiation

42

Evidence quality

48

Translational signal

45

Research bench value

58

Rationale Harmine’s MAO-A inhibition is mature and unremarkable, but its DYRK1A activity at roughly 30 nM IC50 and the resulting beta-cell proliferation story make it a genuine established-active probe. Evidence is solid but consortium-concentrated; more selective DYRK1A tools now exist, keeping differentiation modest and novelty anchored in the mid-established range.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Beta-carboline reversible MAO-A inhibitor (DYRK1A inhibitor)

A beta-carboline alkaloid from Peganum harmala; a reversible MAO-A inhibitor and DYRK1A kinase inhibitor of interest in beta-cell biology.

Abstract

Harmine (7-methoxy-1-methyl-9H-pyrido[3,4-b]indole; CAS 442-51-3; molecular formula C13H12N2O; molecular weight 212.25) is a beta-carboline alkaloid from Peganum harmala and Banisteriopsis caapi. The compound is a reversible MAO-A inhibitor with similar selectivity profile to harmaline but with the additional well-characterized activity of DYRK1A kinase inhibition (IC50 approximately 30 nM). The DYRK1A activity has generated substantial interest in diabetes research: harmine and related DYRK1A inhibitors stimulate human pancreatic beta-cell proliferation in vitro and in vivo, a long-sought target for diabetes regenerative therapy. Phase 1 trials of derivatives are underway. Plasma half-life is approximately 1 to 3 hours. Used as a research probe for both ayahuasca pharmacology and beta-cell regenerative biology.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-338Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Diphenhydramine

Plain-language summaryIntrigue 50 / 100

Diphenhydramine, sold as Benadryl, is the canonical first-generation antihistamine and the active ingredient in most over-the-counter sleep aids (ZzzQuil, Tylenol PM, Unisom Sleepminis). It blocks H1 receptors for allergy relief but also blocks muscarinic receptors, producing the classic anticholinergic side effect cluster (dry mouth, urinary retention, constipation, confusion). Long-term use, particularly in older adults, has been linked to cognitive impairment and possibly increased dementia risk in observational studies. Newer non-sedating antihistamines like cetirizine or loratadine are preferred for routine allergy control; diphenhydramine remains useful for acute allergic reactions and as an antiemetic. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

30/100

Canonical 1946 sedating antihistamine, well-understood and thoroughly superseded on every therapeutic dimension

Look, diphenhydramine is almost the ideal negative example for what this library is supposed to surface. It was approved in 1946. It’s in Benadryl, ZzzQuil, Tylenol PM, and approximately every OTC sleep product on the drugstore shelf. The mechanism is textbook second-year pharmacology: potent H1 blockade (Ki ~16 nM) combined with broad muscarinic antagonism across M1-M5 (Ki ~70 nM). The sedation is a side effect that got marketed as a feature. Thats not a research hook, thats a liability someone repackaged.

The anticholinergic burden is the most scientifically active conversation around this compound right now, and the news is not good. The BEERS Criteria flag it explicitly as potentially inappropriate in older adults. Long-term use epidemiology associates it with meaningful dementia risk. The Anticholinergic Cognitive Burden scale uses it as a reference entry. So the “interesting” research angle here is essentially “how bad is this for brains” rather than any forward-looking therapeutic story.

On differentiation: second-generation antihistamines (cetirizine, fexofenadine, loratadine) were developed for the specific purpose of removing exactly what makes diphenhydramine problematic. They strip the CNS penetration, reduce the anticholinergic load, and retain the H1 efficacy. In allergy indications, the second-gen compounds are strictly better. Diphenhydramine survives as an OTC sleep aid because sleepiness is the desired endpoint there, not because it’s pharmacologically refined.

We’ll give it credit where it’s due: the evidence base is massive. Multiple approved indications, well-replicated pharmacokinetics (plasma half-life 4-8 hours, reasonable oral bioavailability), a clear human signal for its approved uses. But strong evidence for tired indications isn’t what this library tracks. What we care about is whether a serious investigator should spend time on it, and the answer is almost never unless they’re specifically studying anticholinergic burden mechanisms or running assay comparisons as a reference standard for H1 pharmacology.

The bench utility is real but narrow. It appears in receptor selectivity panels, ACB scoring research, and as a comparator in antihistamine profiling studies. Thats legitimate. It’s not the kind of indispensable probe that defines what’s possible in a research area. It’s more of a known quantity you include in a table to anchor your assay.

Honestly, the score of 30 probably feels generous given how thoroughly this compound has been superseded. The evidence quality axis pulls it up because 75 years of replicated pharmacology is hard to ignore. But novelty at 5 and mechanism at 12 are where the real story lives: this compound solved a problem in 1946 that was solved more elegantly by 1995. Research time is better spent elsewhere.

Novelty

5

Mechanism promise

12

In-category differentiation

20

Evidence quality

75

Translational signal

55

Research bench value

35

Rationale Diphenhydramine scores near-zero on novelty (1946 approval, OTC ubiquity) and mechanism promise (dual H1/muscarinic antagonism, both trivially understood); evidence quality is high but reflects 75 years of boring clinical confirmation, not frontier signal. No structural cap formally applies, but the raw calculation lands at 30 anyway.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

First-generation H1 antihistamine + anticholinergic

An ethanolamine first-generation H1 antihistamine; the canonical sedating antihistamine and OTC sleep aid.

Abstract

Diphenhydramine (2-(diphenylmethoxy)-N,N-dimethylethanamine; CAS 58-73-1; molecular formula C17H21NO; molecular weight 255.36) is an ethanolamine first-generation H1 antihistamine developed at Parke-Davis and approved in 1946. The compound is the canonical sedating H1 blocker (Ki approximately 16 nM) with significant anticholinergic activity (M1-M5 antagonism, Ki approximately 70 nM). The combined activity produces sedation, dry mouth, blurred vision, and confusion (especially in elderly). Plasma half-life is approximately 4 to 8 hours. Approved indications: allergic conditions, motion sickness, parkinsonism, anaphylaxis. OTC sleep aid use in branded products (Tylenol PM, ZzzQuil) is widespread despite limited efficacy and concerning anticholinergic burden in elderly (associated with dementia risk in long-term use per BEERS criteria). The compound has dose-dependent abuse potential at high doses (deliriant effect from anticholinergic activity). Used as the canonical first-generation H1 antihistamine in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-354Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Liposomal Glutathione

Plain-language summaryIntrigue 50 / 100

Liposomal glutathione is the body’s master antioxidant (a small protein called glutathione, or GSH) packaged inside tiny fat bubbles called liposomes. The trick is delivery. Plain oral glutathione is largely destroyed in the gut, so the liposome shell is meant to protect it long enough to reach the bloodstream and possibly take a lymphatic shortcut. A handful of small clinical studies suggest it raises blood and intracellular glutathione better than plain oral glutathione, but the picture is far from settled. Many researchers argue NAC (which lets cells build their own glutathione) does the same job for less money. Used in oxidative-stress research and as a supplement. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished workhorse

31/100

Delivery-optimized GSH formulation with modest clinical signal but no new biology

Look, glutathione is about as foundational as it gets in redox biology. The GSH/GSSG ratio, phase II detoxification, glutathione peroxidase cascades – this is textbook biochemistry from the 1970s and 1980s. Liposomal encapsulation is a genuinely clever fix for a real problem: native oral glutathione gets chewed up by intestinal proteases before it reaches systemic circulation, so plasma elevation from unprotected oral dosing has historically been poor.

The phosphatidylcholine encapsulation story makes mechanistic sense. Protecting the tripeptide from proteolytic degradation, potentially routing absorption through the chylomicron and lymphatic pathway – its a plausible engineering solution to a known limitation. And published trials do show liposomal formulations outperforming plain oral GSH on plasma and intracellular markers. Richie et al. (2015) in the European Journal of Nutrition is probably the most-cited work here, showing dose-dependent GSH increases over four weeks in healthy adults. Thats real data, not marketing copy.

Here’s the thing though: “better than plain oral glutathione” is a low bar, and it doesn’t resolve whether this is the right tool. NAC raises glutathione via de novo synthesis rather than direct delivery, carries several decades of clinical evidence including robust data in acetaminophen overdose and pulmonary conditions, and costs a fraction of liposomal GSH. The head-to-head is genuinely unsettled in the literature. That debate is real, but it’s a debate about delivery logistics, not new biology.

What we don’t see with liposomal glutathione is a novel research question it uniquely enables. For in vitro work, you add GSH directly to media. For animal depletion models, buthionine sulfoximine is the clean probe. For IV administration in human studies, established IV protocols exist. The liposomal oral form fills a specific niche – convenient, non-invasive, better absorbed than plain oral – but that’s a product story, not a research frontier.

The novelty here is in delivery engineering, and even that isn’t particularly fresh. Liposomal formulations have been a pharmaceutical tool since the late 1960s. Applying them to glutathione is a sensible extension but doesn’t define a new area of investigation. We’re not generating new mechanistic knowledge about redox networks or glutathione metabolism with this formulation. Honestly, if your research program genuinely requires elevated systemic glutathione in a non-IV setting, this is worth knowing about. But as a compound that might anchor a research program? The science here is settled, not frontier.

Novelty

30

Mechanism promise

22

In-category differentiation

38

Evidence quality

33

Translational signal

33

Research bench value

35

Rationale Liposomal encapsulation addresses a real bioavailability limitation of oral glutathione, and small clinical trials confirm improved plasma levels, but the underlying mechanism is entirely settled, NAC competes on most dimensions with far deeper evidence, and the compound opens no novel research questions.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Glutathione (liposomal formulation)

L-glutathione encapsulated in phospholipid liposomes for improved oral absorption.

Abstract

Liposomal glutathione (L-glutathione encapsulated in phosphatidylcholine-based liposomes; native GSH CAS 70-18-8; molecular formula C10H17N3O6S; molecular weight 307.32) is a delivery system for the master antioxidant glutathione developed to address the poor oral bioavailability of native glutathione. The phospholipid bilayer protects the tripeptide from gastric and intestinal proteolysis and may facilitate intestinal uptake through chylomicron-mediated lymphatic absorption. Limited published clinical trials suggest improved plasma and intracellular glutathione elevation compared to non-liposomal oral forms, though comparative effectiveness against NAC (which raises GSH via biosynthesis rather than direct delivery) is debated. Used as a research-grade and supplement-grade glutathione formulation.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-371Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Estradiol (Research)

Plain-language summaryIntrigue 70 / 100

Estradiol (E2) is the principal endogenous estrogen, made from testosterone and androstenedione by the enzyme aromatase in ovary, fat, brain, and bone tissue. It is a high-affinity full agonist at both estrogen receptor subtypes (ER-alpha and ER-beta), driving classic gene-transcription effects plus rapid membrane-level signaling. Approved across many forms (oral, transdermal patch, gel, vaginal, injectable) for menopausal hormone therapy, postmenopausal osteoporosis prevention, hypoestrogenism in conditions like Turner syndrome, and as part of gender-affirming feminizing therapy. Pharmacokinetics depend heavily on route: oral undergoes large first-pass metabolism, while transdermal forms bypass the liver and produce more physiological plasma levels. Reference estrogen receptor agonist for endocrine research. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundResearch workhorse

45/100

The canonical endogenous estrogen: indispensable as a reference probe, biologically too mapped to excite frontier researchers

Look, estradiol isn’t a research compound in the sense the Kodiac library is trying to surface. It’s the endogenous estrogen. It’s been known since Doisy and Butenandt in the 1920s and 30s, it defines estrogen receptor pharmacology the way glucose defines glycolysis, and the mechanism is so thoroughly described that a first-year grad student can recite it: high-affinity full agonism at both ER-alpha and ER-beta (Ki around 0.1 nM at each), genomic effects through estrogen response elements, rapid non-genomic signaling through membrane-associated ER pools, aromatase as the biosynthetic gateway. There is nothing left to discover about what estradiol IS. The question is only ever what it DOES in some specific tissue, population, or formulation context that hasnt been nailed down yet.

That context matters, because the literature is genuinely enormous. The Women’s Health Initiative, the KEEPS trial, the E3N cohort, decades of transdermal vs oral comparative pharmacokinetics, the whole bioidentical vs conjugated equine estrogens debate, the ER-alpha vs ER-beta tissue selectivity question as it applies to bone, breast, cardiovascular, and CNS targets. The evidence base is as strong as anything in endocrine pharmacology. Multiple approved formulations across oral, transdermal, vaginal, and parenteral routes. If evidence quality alone drove the score, estradiol would be at the top of this list. But evidence quality is 15% of the rubric for a reason.

What we like: estradiol remains the reference probe you can’t avoid. Any investigator running ER biology needs it as a positive control and comparator. It’s the benchmark against which every SERM, SERD, and ER-selective agonist is calibrated. In that narrow but important role, its bench value is genuine and non-negotiable. The ongoing translational signal is also real, particularly in the neuroprotection, cardiovascular, and metabolic contexts where estrogen deprivation models are active research territory.

What we don’t like: as a frontier target, theres almost nothing here. The interesting estrogen receptor biology right now is happening in selective tools. ER-alpha vs ER-beta subtype selectivity probes, tissue-selective ER modulators, SERDs in oncology, the brain-specific ER-X question. Estradiol itself activates everything, which makes it blunt as a discriminating probe. If youre building a new research program around estrogen biology, estradiol is your positive control, not your compound of interest. The novelty score reflects that honestly: this is among the most mature, most-mapped pharmacology in the field.

The score of 45 is the right landing zone. High enough to acknowledge that it’s genuinely important and evidence-rich, low enough to be honest that a serious bench scientist wouldn’t pitch this as an exciting new direction. It’s what you reach for when validating an assay, not when designing a study.

Novelty

10

Mechanism promise

18

In-category differentiation

42

Evidence quality

82

Translational signal

78

Research bench value

72

Rationale Estradiol tanks on novelty and mechanism because ER-alpha/ER-beta pharmacology is among the most exhaustively characterized biology in all of endocrinology; it recovers meaningfully on evidence quality and translational signal (decades of RCTs, multiple approvals) and holds respectable bench value as the canonical ER reference probe, but that utility is increasingly eclipsed by selective ER modulators and degraders that can discriminate receptor subtype biology more cleanly.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Endogenous estrogen / ER-alpha and ER-beta agonist

17-beta-estradiol; the principal endogenous estrogen and the foundational compound of estrogen pharmacology.

Abstract

Estradiol (17-beta-estradiol, E2; CAS 50-28-2; molecular formula C18H24O2; molecular weight 272.39) is the principal endogenous estrogen, biosynthesized from testosterone (and androstenedione) by aromatase in ovary, adipose tissue, brain, and bone. The compound is a high-affinity full agonist at estrogen receptors ER-alpha and ER-beta (Ki approximately 0.1 nM at both), with downstream genomic effects on estrogen-responsive gene transcription and rapid non-genomic effects through membrane-associated signaling. Approved indications include menopausal hormone therapy (multiple oral, transdermal, vaginal, and parenteral formulations), prevention of postmenopausal osteoporosis, hypoestrogenism (Turner syndrome), and as part of gender-affirming feminizing hormone therapy. Pharmacokinetics depend strongly on formulation: oral micronized estradiol undergoes substantial first-pass metabolism; transdermal forms (patches, gels, sprays) bypass first-pass and produce more physiological plasma levels. Schedule N (non-controlled). Used as the canonical estrogen receptor agonist in research.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-387Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Galantamine

Plain-language summaryIntrigue 70 / 100

Galantamine, sold as Razadyne, is a natural alkaloid (originally from snowdrops) that inhibits acetylcholinesterase and positively modulates nicotinic receptors. FDA-approved for Alzheimer disease. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

52/100

Dual AChE inhibitor and alpha-7 nAChR PAM approved in 2001, mature but mechanistically distinct from its class

Look, galantamine is one of those compounds where the mechanism story is more interesting than the clinical story, and both are older than you probably want them to be. FDA-approved in 2001 as Razadyne, it’s been a fixture of the Alzheimer’s pharmacopoeia for a quarter-century. That alone tells you where the novelty axis lands, and it lands low.

Here’s what keeps galantamine worth discussing: the dual mechanism. Most AChE inhibitors are just AChE inhibitors. Galantamine also functions as a positive allosteric modulator at nicotinic acetylcholine receptors, particularly alpha-7 and alpha-4-beta-2 subtypes. That PAM activity isn’t a footnote. Alpha-7 nAChR signaling is implicated in attention, synaptic plasticity, and neuroinflammation through the cholinergic anti-inflammatory pathway, and PAMs are generally considered cleaner probes than direct agonists because they require endogenous acetylcholine for activity. Mechanistically, that’s sound pharmacology. Galantamine’s Ki for AChE sits around 360 nM, substantially weaker than donepezil, which likely reflects the biological space the PAM activity is expected to fill. It’s an intentionally balanced dual-mechanism profile, not just a weaker inhibitor.

The translational story, though, is modest by any honest read. In phase 3 trials galantamine performs in roughly the same tier as donepezil, with some groups reporting marginal advantages on attention and behavioral symptoms. Some investigators find the profile useful in dementia with Lewy bodies, and theres a sparse but real schizophrenia-adjacent literature exploring the alpha-7 PAM angle for cognitive symptoms. But effect sizes are small across the board, and the AD indication has clearly moved toward amyloid-targeting biologics, tau-based approaches, and later-generation mechanisms. Galantamine is not where the frontier is.

What it does retain is genuine bench utility as a dual-mechanism probe. If you’re studying cholinergic contributions to cognition or dissecting AChE inhibition from nicotinic PAM activity, comparing galantamine against single-mechanism compounds is a legitimate experimental approach. The sourcing is straightforward given its approved status, pharmacokinetics are well-characterized, and the CYP2D6/3A4 metabolic profile is fully documented. For investigators working on alpha-7 biology, neuroinflammation modulation, or nicotinic contributions to psychiatric phenotypes, its a credible tool.

We dont see galantamine as an exciting primary research target in 2026. The mechanism is thoroughly characterized, the clinical indication is mature and migrating away from small molecules, and nothing in the current literature suggests a surprise. But for a research library that serves bench investigators working in cholinergic and nicotinic pharmacology, it earns its place as a well-understood dual-mechanism reference compound. Worth having available; not worth building a program around.

Novelty

22

Mechanism promise

62

In-category differentiation

45

Evidence quality

75

Translational signal

65

Research bench value

52

Rationale Galantamine’s PAM activity at alpha-7 and alpha-4-beta-2 nicotinic receptors is the only axis where it genuinely differentiates from other AChE inhibitors, but the compound is 25 years post-approval and the clinical effect size in AD is modest; the dual mechanism retains meaningful probe utility for cholinergic and nicotinic research programs without justifying a high novelty or differentiation score.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Selective acetylcholinesterase inhibitor + alpha-7 nAChR PAM

A natural alkaloid from Galanthus and Narcissus species, FDA-approved as Razadyne for Alzheimer disease, distinguished by dual AChE inhibition and nicotinic receptor allosteric modulation.

Abstract

Galantamine (Razadyne, Reminyl; CAS 357-70-0; molecular formula C17H21NO3; molecular weight 287.36) is a tertiary amine alkaloid extracted originally from Galanthus nivalis (snowdrop) and Narcissus species, approved by the FDA in 2001 for mild-to-moderate Alzheimer disease and now produced synthetically. The compound is a selective reversible acetylcholinesterase inhibitor (Ki approximately 360 nM) with substantially weaker AChE inhibition than donepezil, but with a distinctive secondary mechanism that distinguishes it from other AChE inhibitors used clinically: galantamine is a positive allosteric modulator (PAM) of nicotinic acetylcholine receptors, particularly the alpha-7 and alpha-4-beta-2 subtypes most relevant to cognition. The dual mechanism produces a clinical profile considered slightly different from donepezil; some investigators report better effects on attention and behavioral symptoms. Pharmacokinetics: plasma half-life 7 hours; oral bioavailability essentially complete; metabolism is hepatic via CYP2D6 and CYP3A4. Approved doses are 16 to 24 mg per day in two divided administrations; lower starting doses minimize gastrointestinal adverse events. Schedule status: prescription-only but not federally scheduled.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-045Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Bromantane

Plain-language summaryIntrigue 62 / 100

Bromantane is a Russian-developed adamantane-derived adaptogen used to enhance physical and mental performance. It modulates dopamine and serotonin systems and is approved in Russia for asthenia. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

47/100

Soviet actoprotector with a genuinely unusual dual mechanism, hampered by opaque Russian-only clinical evidence

Look, bromantane is one of those compounds that sits in an awkward spot. It’s been around since the 1980s Soviet military program, it’s approved as Ladasten in Russia, and it’s been on the WADA prohibited list since 1996. None of that is new. But the mechanism is still genuinely strange enough to reward a second look, and thats what makes it worth having in the library at all.

Here’s what we find interesting: bromantane doesn’t do what you’d expect from a stimulant or an anxiolytic. Most dopaminergic compounds work by blocking reuptake (amphetamines, methylphenidate), promoting release (amphetamines again), or receptor agonism. Bromantane enhances dopamine synthesis upstream. The proposed pathway runs through increased tyrosine hydroxylase and DOPA decarboxylase expression, essentially turning up the production line rather than manipulating the distribution end. That’s a meaningfully different intervention point, and as a research probe for studying endogenous dopamine regulation it has some real appeal. The anxiolytic piece is equally odd: non-GABAergic, mechanism not fully resolved, but the clinical profile consistently distinguishes it from benzos and from sedating antihistamines.

The actoprotector concept it was built around, improving physical and cognitive performance under sustained stress without stimulant rebound or sedative blunting, maps onto real biology even if that specific Soviet framing doesnt always translate cleanly into Western pharmacology. There’s a plausible stress-resilience program you could design around bromantane as a tool.

What we don’t like: the evidence situation is uncomfortable. Substantial Russian clinical literature exists, including registration trials supporting the Ladasten approval, but the bulk of it isn’t easily accessible in English, and the methodological standards of Russian regulatory trials from the late 1990s through 2000s are hard to assess from outside that system. English-language RCTs are sparse. We can’t point to a multi-lab replication story the way we can for something like ipamorelin or BPC-157. The WADA ban is indirect evidence of real biological effect, but that’s a thin reed for a research program.

Honestly, bromantane slots in as a mechanistically distinctive but evidence-limited compound. We think researchers interested in dopamine synthesis biology or in the pharmacology of stress adaptation without stimulant side effects will find it worth cataloguing. But it’s not something you’d build a primary research program around without first sorting out the translational evidence gap. The mechanism promise is real; the replication story isn’t there yet.

Novelty

38

Mechanism promise

58

In-category differentiation

57

Evidence quality

38

Translational signal

42

Research bench value

42

Rationale Bromantane’s core interest lies in its mechanistic combination: dopamine synthesis upregulation (not release, not transporter inhibition) paired with non-GABAergic anxiolysis. That dual profile is genuinely differentiated. The drag is evidence quality: the clinical literature is substantial but almost entirely Russian-language, which makes independent verification difficult and keeps evidence and translational scores well below what a Western-replicated program would earn.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Adamantane-derived adaptogen

A Soviet-developed adamantane derivative (Ladasten) approved in Russia for asthenia with mixed psychostimulant and anxiolytic effects.

Abstract

Bromantane (Ladasten; ADK-709; N-(2-adamantyl)-N-(p-bromophenyl)amine; CAS 87913-26-6; molecular formula C16H20BrN; molecular weight 306.24) is an adamantane derivative developed in the Soviet Union in the 1980s, originally for military applications (combat fatigue, cold tolerance). The compound is approved in Russia as Ladasten for asthenia and neurasthenia. Pharmacology is distinctive: bromantane combines mild dopaminergic activation (through enhanced dopamine synthesis rather than transporter inhibition or release) with anxiolytic effects through a non-GABAergic mechanism. The combination produces a clinical profile described as “actoprotective” . improving physical and mental performance under stress without the rebound fatigue typical of stimulants or the sedation typical of anxiolytics. Bromantane is on the WADA prohibited list (banned in 1996). Pharmacokinetics: plasma half-life 9 to 12 hours; oral bioavailability good. Doses are 50 to 100 mg per day. Russian clinical literature is substantial; English-language randomized trials are limited.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-063Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026
Tesamorelin

Plain-language summaryIntrigue 70 / 100

Tesamorelin, sold as Egrifta, is a stabilized GHRH analog FDA-approved for HIV-associated visceral fat accumulation. It produces growth hormone release while preserving the natural pulsatile pattern. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Our opinion on this compoundEstablished, active research

57/100

FDA-approved GHRH analog with proven visceral fat reduction and an emerging cognitive research angle worth watching

Look, tesamorelin occupies a genuinely interesting position in the GHRH analog space, and that position is mostly defined by what it has that its competitors dont: a real FDA approval backed by actual phase 3 data. Egrifta got its 2010 nod for HIV-associated lipodystrophy, and that approval is anchored in legitimate multicenter RCTs, not the kind of single-lab preclinical story you see from most peptides in this category. For visceral adipose tissue reduction in patients on antiretroviral therapy, it works, and we have the data to say so with confidence.

The structural story is worth understanding. Native GHRH has a plasma half-life in the 7-10 minute range; sermorelin gets you to roughly 11-12 minutes. Tesamorelin’s trans-3-hexenoic acid conjugation at the N-terminus pushes that to around 26 minutes, and more importantly, it preserves the natural pulsatility of GH release. Thats not a trivial distinction. Exogenous GH replacement suppresses endogenous axis function; tesamorelin stimulates it. Mechanistically that’s the cleaner approach, and researchers interested in GH axis physiology have a real reason to reach for it as a probe compound rather than just injecting GH directly. The downstream IGF-1 signal is physiological, not pharmacological, which matters if you’re trying to isolate axis-specific effects.

Where the score gets complicated is novelty. GHRH analogs are a mature class. CJC-1295 with DAC has a dramatically longer half-life if you’re chasing PK. Sermorelin is cheap and accessible. The tesamorelin story really rests on two things: the regulatory anchor, which you can’t dismiss, and an emerging cognitive research thread that we think is the most interesting active science around this compound right now. Multiple investigator groups have looked at tesamorelin in the context of HIV-associated neurocognitive disorder, with a modest but real signal appearing across several small trials. Whether the effect is GH-mediated, IGF-1-mediated, or something more indirect through neuroinflammatory or metabolic pathways is still being worked out, and that ambiguity is actually what makes it worth watching for any program focused on the neuroendocrine-cognition intersection.

Honestly, for a bench scientist the most defensible use case is as a validated GHRH-axis tool with a real human pharmacokinetic and pharmacodynamic dataset behind it, which is more than most peptides in this class can claim. Sourcing is cleaner than average given approved-drug status and peptide-synthesis availability. We’d put this in the serious-but-not-urgent category: real signal, real data, mechanism that’s established rather than exciting. The cognitive angle could shift the assessment if the next round of trials holds up, but right now it reads as confirmatory work on a known platform rather than something at the frontier.

Novelty

40

Mechanism promise

45

In-category differentiation

62

Evidence quality

72

Translational signal

72

Research bench value

55

Rationale Tesamorelin’s trans-3-hexenoic acid modification and its FDA approval in HIV lipodystrophy give it unusually strong evidence and translational scores for a peptide, but the mechanism is single-receptor agonism in a mature class and novelty is correspondingly modest. The HIV-associated neurocognitive disorder research thread is the most scientifically interesting active direction and keeps it from scoring lower.

Editorial commentary from Kodiac biolabs. Not a recommendation, not clinical advice. Research use only.

Stabilized GHRH analog

A trans-3-hexenoic acid stabilized GHRH analog FDA-approved as Egrifta for HIV-associated lipodystrophy.

Abstract

Tesamorelin (Egrifta; CAS 901758-09-6; molecular weight 5135.79) is a stabilized analog of human GHRH developed by Theratechnologies (Canada) and approved by the FDA in 2010 for HIV-associated lipodystrophy. The structural modification is the addition of a trans-3-hexenoic acid group at the N-terminus, which substantially extends plasma half-life relative to native GHRH or sermorelin. The compound stimulates physiological GH release with restored visceral adipose tissue reduction in HIV patients on antiretroviral therapy. Pharmacokinetics: plasma half-life approximately 26 minutes (versus 11 to 12 minutes for sermorelin); subcutaneous administration. Approved dose is 2 mg subcutaneously once daily.

Read the full monograph

The full reference document covers compound identification, discovery and developmental history, mechanism of action, pharmacokinetics, sourcing and quality verification, and a curated reference list. Embedded inline below; download for offline reading.

KDC-MN-080Open in new tab →

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

May 9, 2026

←Previous Page

1 … 59 60 61 62 63 … 69

Bench-grade research compounds. Cited research. Verified COAs.

kodiac.bio

Explore

Shop
Monographs
Lab Results
About
Affiliate program
Affiliate handbook

Account

Cart
My account

Help

Compliance
Contact

Quarterly dispatch

New batches and new monographs only. Unsubscribe in one click.

Write to us from the contact page to join the list.

Kodiac biolabs sells research compounds for in vitro and in vivo investigative purposes only. Products are not for human or veterinary consumption. Not for medical, diagnostic, or therapeutic use. By using this site you confirm you are acquiring research compounds for research purposes only.

Kodiac biolabs is not affiliated with the U.S. Food and Drug Administration. Products are research reagents, have not been evaluated by the FDA, and are not intended to diagnose, treat, cure, or prevent any disease.

© 2026 Kodiac biolabs LLC. All rights reserved.